Home
/
Our Pipeline

A Deep Pipeline of Allogeneic, Off-The-Shelf Virus-Specific T cell (VST) Therapy Candidates Targeting Twelve Viruses

A large number of patients suffering from devastating viral diseases currently have limited or no treatment options. To address this, we are advancing a pipeline of allogeneic, off-the-shelf VST therapy candidates to treat or prevent life-threatening viral diseases.
Posoleucel (Viralym-M, ALVR105)
Multi-VSTs targeting BK Virus (BKV), Cytomegalovirus (CMV), Adenovirus (AdV), Epstein-Barr (EBV), and Human Herpesvirus-6 (HHV-6)
Target Indication
Target Population
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of Virus-Associated Hemorrhagic-Cystitis
Allo-HSCT
Treatment of CMV
Allo-HSCT
Treatment of ADV
Allo-HSCT
Prevention of BKV, CMV, AdV, EBV, HHV-6 and JCV
Allo-HSCT
Treatment of BKV
Kidney Transplant
Treatment of CMV
Solid Organ Transplant
Posoleucel (Viralym-M, ALVR105)
Multi-VSTs targeting BK Virus (BKV), Cytomegalovirus (CMV), Adenovirus (AdV), Epstein-Barr (EBV), and Human Herpesvirus-6 (HHV-6)
Target Indication
Target Population
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of Virus-Associated Hemorrhagic-Cystitis
Allo-HSCT
Treatment of CMV
Allo-HSCT
Treatment of ADV
Allo-HSCT
Prevention of BKV, CMV, AdV, EBV, HHV-6 and JCV
Allo-HSCT
BKV Pre-emptive Treatment in KT
Kidney Transplant
Treatment of CMV
Solid Organ Transplant
ALVR106
Multi-VSTs targeting Respiratory syncytial virus (RSV), Influenza, Parainfluenza Virus (PIV), and Human Metapneumovirus (hMPV)
Target Indication
Target Population
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of RSV, Influenza, PIV, & hMPV
Allo-/Auto-HSCT
IND Cleared in Q4 2020
Treatment of RSV, Influenza, PIV, & hMPV
High-risk general population*
ALVR109
Single-VST targeting SARS-CoV-2
Target Indication
Target Population
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of COVID-19
High-risk general population*
ALVR107
Single-VST targeting Hepatitis B (HBV)
Target Indication
Target Population
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of HBV
Patients with chronic HBV
ALVR108
Single-VST targeting Human Herpesvirus-8 (HHV-8)
Target Indication
Target Population
Preclinical
POC Trial (Phase 1b/2)
Pivotal Trial (Phase 3)
Treatment of HHV-8
Patients with KS, MCD, or PEL
Definitions
Allo-HSCT: allogeneic HSCT; Auto-HSCT: autologous HSCT; KS: Kaposi Sarcoma; MCD: Multi-centric Castleman Disease; PEL: Primary Effusion Lymphoma; POC: Proof-of-concept; High-risk general population: immunocompromised cancer patients, the elderly, and very young
Expanded Access

We Treat High-Risk Individuals

Our allogeneic, off-the-shelf VST therapy candidates benefit patients with T cell deficiencies including transplant recipients, immunocompromised cancer patients, the elderly, and the very young at a higher risk of the devastating consequences of viral disease.
Life-Threatening Viral Infections
Uncontrolled Viral Diseases Cause End-Organ Damage and Mortality
BK Virus
Cytomegalovirus
Adenovirus
Epstein-Bar Virus
Human Herpesvirus-6
Parainfluenza Virus
Human Metapneumovirus
Influenza Virus
Respiratory Syncytial Virus
SARS-CoV-2
Hepatitis B Virus
Human Herpesvirus-8
Bladder
Severe hemorrhagic cystitis
Urinary obstruction
Cystectomy
Brain
Severe encephalitis
Seizure
Memory defect
Progressive Multifocal Leukoencephalopathy
Kidneys
Nephritis
Acute/chronic renal failure
End stage renal disease
Lungs
Pneumonia
Bronchitis
Respiratory failure
Eyes
Retinitis
Blindness
Liver
Chronic hepatitis
Liver cirrhosis
Hepatocellular Carcinoma
Small/Large Intestine
Colitis
Ulceration / perforation
Intestinal bleeding
Malignancy
Kaposi sarcoma
Primary Effusion
Lymphoma (PEL)

AlloVir is the Global Leader in Developing VST Immunotherapies

We develop highly innovative allogeneic, off-the-shelf VST therapy candidates designed to treat or prevent devastating viral infections and diseases.

Our Pipeline

Our allogeneic, off-the-shelf, VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.
view

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.
learn

Our People

Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.
meet

Cambridge

139 Main Street
Suite 500
Cambridge, MA 02142

Houston

2925 Richmond Ave
Suite 1200
Houston, TX 77098

Company

About UsContact Us617-433-2605
ContactCareers
AlloVir ©2021 All rights reserved
Privacy & Cookie Policy
Expanded Access

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno